SCHEMBL2349673

SCHEMBL2349673

COc1cc(C(N)=O)c(-c2ccc[nH]c2=O)cc1C(C)(C)C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 1/20 0.37
PARP1 P09874 3/20 0.37
CYP3A4 P08684 4/20 0.37
IKBKB O14920 2/20 0.36
CHUK O15111 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CDC7 O00311 1/20 0.35
CHEK1 O14757 1/20 0.35
ERBB2 P04626 1/20 0.35
LMNA P02545 2/20 0.35
TP53 P04637 1/20 0.35
HPGD P15428 1/20 0.35
ALOX15 P16050 1/20 0.35
IMPDH2 P12268 1/20 0.35
IMPDH1 P20839 1/20 0.35
CD274 Q9NZQ7 1/20 0.35
ALPL P05186 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2350724 0.89 NAPRT (0.43) CYP1A1CYP3A4L3MBTL1ERBB2LMNA
SCHEMBL2362083 0.86 PLK1 (0.38) CYP1A1CYP3A4L3MBTL1ERBB2LMNA
SCHEMBL3316087 0.86 MAP4K1 (0.38) CYP1A1CYP3A4L3MBTL1CHEK1ERBB2
SCHEMBL2354432 0.84 KDM4E (0.40) CYP3A4L3MBTL1LMNAHPGDNPC1
SCHEMBL2364691 0.83 ICMT (0.44) CYP1A1CYP3A4L3MBTL1ERBB2LMNA
SCHEMBL2362084 0.83 CYP3A4 (0.37) CYP3A4IKBKBL3MBTL1CD274NPC1
SCHEMBL2364476 0.82 CYP1A1 (0.35) CYP1A1CYP3A4L3MBTL1ERBB2LMNA
SCHEMBL13329976 0.81 ADRA2A (0.42) CYP1A1CYP3A4L3MBTL1ERBB2LMNA
SCHEMBL3313129 0.81 CYP3A4 (0.36) CYP1A1CYP3A4L3MBTL1LMNAIMPDH2
SCHEMBL2362966 0.81 HCRTR1 (0.36) CYP1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232271-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-07-31 US claimed
EP-2350007-A1 HETEROCYCLIC ANTIVIRAL ARYLPYRIDONE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2011-08-03 EP claimed
US-20100111900-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ROCHE PALO ALTO LLC 2010-05-06 US claimed
WO-2010049331-A1 HETEROCYCLIC ANTIVIRAL ARYLPYRIDONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-05-06 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100111900-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS POLR2A, EIF2AK2, POLR2B CYP1A1 312/4885PARP1 482/4885CYP3A4 423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.